Myelodysplastic syndromes (MDS) are the most common hematological malignancies involving mainly the elderly. They are defined as clonal stem cell disorders and characterized by ineffective hematopoiesis involving one to all bone marrow cell lineages [1]. The dominant morbidity of MDS relates to symptomatic cytopenias.
According to various reports the annual incidence of MDS ranges widely from 2 to 12 per 100,000, increasing to 30–50 cases per 100,000 among persons aged 70 or older. It is believed that the true incidence of MDS has been underestimated
and appears to be comparable to that of multiple myeloma and chronic lymphocytic leukemia [2, 3].
MDS may arise de novo, or as a result of previous environmental damage, or chemo-or radiotherapy with a peak incidence at 2–4 years following the initial exposure [4]. It might therefore be hypothesized that MDS arises due to cumulative environmental exposure in genetically predisposed individuals [5]. MDS may be regarded as a progression model in which the acquisition of genetic events occur by gain or loss of genetic material.
MDS was previously named “preleukemia” or “smoldering leukemia” with a lack of terminal cells due to high apoptosis rate and the subsequent failure of differentiation. In about 25% of all cases when MDS progresses to AML—stem cell apoptosis stops and the cells fail to differentiate, a process that has been widely studied. In the past decade much progress had been achieved. We know more about disease pathophysiology resulting in increased emphasis on patient care and the evolution of targeted therapy.
The chapters of this book offer updated knowledge on all clinically important aspects of the disease. Topics of great current interest are discussed by leading authors on MDS from different parts of the world. We would like to recommend this book to all those interested in this exciting and rapidly expanding field of hematology, including. medical students and postgraduates.
Although MDS is a clonal disease it is not yet recognized as a malignant disease by the majority of health care systems. Consequently, access of MDS patients to novel, expensive and targeted therapeutic modalities is generally unsatisfactory. It is hoped that the present volume will increase awareness of the necessity of optimal treatment beyond simple supportive measures and facilitate the introduction of optimal treatment adequately sponsored by decision makers in health care systems.
References
1.Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JCY, Schimmer AD (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 7:118–129
2.Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders
in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008 112(1):45–52
3.Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM (2008) Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 87:691–699
4.Raposa T, Várkonyi J (1987) The relationship between sister chromatid exchange induction and leukemogenicity of different cytostatics. Cancer Detect Prev 10(1–2):141–151
5.Willman C (2001) MDS/AML: models of genetic progression and clues to etiology. Leukemia Res 25(1):1 (Abstr. Or3)
Myelodysplastic syndromes (MDS) are the most common hematological malignancies involving mostly the elderly population. The major morbidity relates to patients’ symptomatic cytopenias.MDS was previously named as “preleukemia “ or “ smoldering leukemia” as the lack of terminal cells in MDS and because about 25% of all cases progresses into acute myeloid leukemia.
According to various reports the annual incidence of MDS ranges widely from 2-12 per 100.000, increasing to 30-50 cases per 100.000 among persons aged 70 or older. It is believed that the true incidence of MDS have been underestimated however it seems to be comparable to that for multiple myeloma and chronic lymphocytic leukemia.
In the past decade much progress had been made; we know more on the disease pathology, there is more emphasis on the care and more targeted therapy had been invested.
Athors provide updated knowledge in this book on all clinically important aspects of the disease. Hot topics of our days are discussed in chapters by outstanding and well known scientists from all over the world. We would offer this product both for medical students and postgraduates as well as for all who are interested in this very exciting and fast progressing field of hematology.
With this work authors should call attention on the disease for decision makers in healt care systems as well.
Contents
- Chapter 1. The History of the Myelodysplastic Syndromes
- Chapter 2. Susceptibility to MDS: DNA Repair and Detoxification Genes
- Chapter 3. Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical Features and Standard Evaluation
- Chapter 4. Diagnostic Criteria and Classification of Myelodysplastic Syndromes
- Chapter 5. Cytogenetics of MDS
- Chapter 6. Molecular Changes in Myelodysplastic Syndrome
- Chapter 7. Prognostic Scoring in MDS
- Chapter 8. Flow Cytometry in Myelodysplastic Syndromes and Arjan A. van de Loosdrecht
- Chapter 9. MDS as an Autoimmune Process
- Chapter 10 The Myelodysplastic Overlap Syndromes
- Chapter 11 Iron and Copper Metabolism in the Myelodysplastic Syndromes
- Chapter 12 Pathogenesis and Management of Iron Overload in MDS
- Chapter 13 Cytokines in MDS: Abnormalities and Treatment
- Chapter 14 Therapeutic Modalities and New Molecular Targets in MDS
- Chapter 15 Haematopoietic Stem Cell Transplantation in MDS for Adults
- Chapter 16 JMML and Myelodysplastic Syndrome in Children
- Appendix
- Index
Book Details
- Hardcover: 299 pages
- Publisher: Springer; 1st edition (March 14, 2011)
- Language: English
- ISBN-10: 9400704399
- ISBN-13: 978-9400704398